- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Neoprobe closes Biosonix deal
Two innovators of medical imaging have joined forces. Biosonix, an Israeli developer of blood flow measurement technology, is now part of Neoprobe, a maker of gamma detection systems used in the management of patients with breast cancer and melanoma. The
Two innovators of medical imaging have joined forces. Biosonix, an Israeli developer of blood flow measurement technology, is now part of Neoprobe, a maker of gamma detection systems used in the management of patients with breast cancer and melanoma. The deal that brought them together, announced Jan. 4, was closed when Neoprobe issued 9,714,737 shares of its common stock in exchange for the outstanding shares of Biosonix. An additional 2,085,826 shares of Neoprobe common stock will be issued to the Biosonix shareholders on the satisfaction of a milestone event involving Biosonix product development activity.
Biosonix products employ angle-independent Doppler blood flow technology that allows angle-independent blood flow volume and velocity readings. The technology permits real-time measurement of volume blood flow. Biosonix has three products in the late stages of development. One, FlowGuard, has received the CE mark for marketing in Europe, but none has yet passed the FDA. At the closing of the deal, Neoprobe appointed Dan Manor and Reuven Avital to its board of directors. Manor, who will remain president of Biosonix, founded the company. Avital, general manager of the investment fund Ma'Aragim Enterprises, held a large stake in Biosonix and is now a major shareholder in Neoprobe.
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
